Areteia Therapeutics Company Profile

Background

Areteia Therapeutics is a clinical-stage biotechnology company established in 2022, dedicated to developing and delivering novel therapies for inflammatory airway diseases, with a primary focus on eosinophilic asthma. The company's mission is to empower respiratory patients by providing innovative treatments that offer better control over their conditions, thereby enhancing their quality of life. Areteia aims to introduce the first oral medication for eosinophilic asthma, addressing a significant unmet need in respiratory care.

Key Strategic Focus

Areteia's strategic focus centers on:

• Development of Dexpramipexole: A first-in-class oral eosinophil maturation inhibitor designed to reduce eosinophil levels in blood and tissue, potentially offering a more accessible and convenient treatment option for patients with eosinophilic asthma.

• Global Clinical Trials: Initiating and expanding Phase III clinical trials across multiple regions, including the U.S., Europe, and Japan, to evaluate the efficacy and safety of dexpramipexole.

• Market Expansion: Targeting the substantial global asthma therapeutics market, which was valued at approximately $17.4 billion in 2022 and is projected to reach around $22.2 billion by 2028, growing at a CAGR of 4.5%.

Financials and Funding

Areteia has secured significant funding to support its development programs:

• Series A Financing: In February 2024, the company announced an additional $75 million in Series A financing, bringing the total Series A funding to $425 million. This round included investments from Viking Global Investors and Marshall Wace, joining the original syndicate led by Bain Capital Life Sciences, with participation from Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, and Population Health Partners.

• Utilization of Funds: The capital raised is intended to expand the ongoing Phase III program, including clinical development in Japan and other global markets, enhance manufacturing activities, and develop a once-daily formulation of dexpramipexole.

Pipeline Development

Areteia's lead investigational candidate is:

• Dexpramipexole: An oral small molecule eosinophil-lowering drug currently in Phase III development for eosinophilic asthma. Dexpramipexole inhibits the maturation of eosinophils in the bone marrow, thereby lowering peripheral blood eosinophil levels.

• Clinical Trials: The company has initiated three global Phase III studies to assess the efficacy and safety of dexpramipexole in patients with eosinophilic asthma.

• Target Conditions: Eosinophilic asthma, a subtype of asthma characterized by elevated eosinophil levels, leading to inflammation and airway obstruction.

• Timelines: The Phase III trials are currently enrolling patients, with anticipated completion and potential regulatory submissions in the near future.

Technological Platform and Innovation

Areteia's innovative approach includes:

• Proprietary Technology: Development of dexpramipexole, a first-in-class oral eosinophil maturation inhibitor.

• Scientific Methodologies: Utilization of advanced clinical trial designs and biomarker analyses to evaluate the efficacy of dexpramipexole in reducing eosinophil levels and improving asthma control.

Leadership Team

Areteia's leadership comprises experienced professionals with extensive backgrounds in biotechnology and pharmaceutical development:

• Jorge Bartolome: Chief Executive Officer

• Peter Wijngaard, Ph.D.: Chief Development Officer

• Calman Prussin, M.D.: Chief Scientific Officer

• Mark Kreston: Chief Commercial Officer

• Christopher Courts, CPA: Chief Financial Officer

• Eric Bradford, M.D.: Chief Medical Officer

• Robin Walker, J.D.: Chief Legal Officer and Corporate Secretary

• Dan Tokich: Head of Global Supply

• Tamsin Berry: Head of Policy and Partnerships

• Shannon Armstrong: Head of Evidence, Market Access, and Value

• Lex Kay: Head of Global Quality

• Richard Fires: Head of Human Resources

Leadership Changes

Recent significant appointments include:

• Ian Read: Appointed as Chairman of the Board in September 2022. Mr. Read brings over 42 years of experience in the biopharmaceutical industry, including his tenure as Chairman and CEO of Pfizer.

• Elyse Stock, M.D.: Joined the Board of Directors in April 2023, bringing extensive experience in clinical and drug development from her previous roles at Biohaven Pharmaceuticals and Bristol-Myers Squibb.

Competitor Profile

Market Insights and Dynamics:

• Asthma Therapeutics Market: Valued at approximately $17.4 billion in 2022, with projections to reach around $22.2 billion by 2028, growing at a CAGR of 4.5%.

• Eosinophilic Asthma Segment: Represents a significant portion of the market, with an estimated 3 million patients in the U.S. and EU suffering from severe eosinophilic asthma.

Competitor Analysis:

• XBiotech: Develops therapeutic antibodies based on its True Human technology, focusing on various inflammatory conditions.

• Kymera Therapeutics: Aims to create medicines for previously untreatable diseases through targeted protein degradation.

• Praxis Precision Medicines: Develops therapies for complex and debilitating brain disorders.

• Synlogic: Focuses on synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases.

Strategic Collaborations and Partnerships

Areteia has established significant partnerships to advance its mission:

• Population Health Partners: Collaborated to create Areteia and advance dexpramipexole through clinical development.